Evaluation of Cyclophilin A in Type II Diabetic Patients with Coronary Artery Disease

Abstract

DM is a metabolic disorder that represents the fifth leading cause of death worldwide. CyPA plays a crucial role in inflammation, vascular contraction, and the development of atherosclerosis. Moreover, the circulating level of MMP9 was associated not only with cardiovascular but also with psychosocial risk factors for coronary artery disease. Therefore, this study was designed to explore the relationship between the circulating levels of CypA and MMP-9 in stable CAD patients with and without T2DM, their possible implication in the pathogenesis, and their diagnostic efficacy for the detection of the disease. This was an observational study conducted on stable CAD patients with and without T2DM. A total of 120 subjects were sequentially recruited from Cardiovascular and Ultrasonography Unit, Research Institute of Ophthalmology, Giza, Egypt in the period from August 2016 to September 2017. Participants were divided equally into four groups: (I) normal healthy volunteers, (II) T2DM patients, (III) stable CAD patients with T2DM, and (IV) stable CAD patients without diabetes mellitus. Informed consent including inclusion and exclusion criteria was taken and a complete history was obtained from all participants before enrollment in this study.